期刊文献+

鹿角方对慢性心力衰竭患者左室重构的干预作用 被引量:17

Intervention Effect of "Lujiao Decoction" on Left Ventricular Remodeling in Patients with Congestive Heart Failure
下载PDF
导出
摘要 目的探讨鹿角方对慢性充血性心力衰竭(CHF)患者左室重构的干预作用。方法将120例CHF患者随机分为鹿角方组、地高辛组和开搏通组,各40例,并给予相应的治疗,疗程3个月。观察临床总有效率、肾虚症状积分、心胸比例、射血分数(EF)、心输出量(CO)、室间隔厚度(IVST)、左室后壁厚度(PWT)、左室重量指数(LVMI)和血浆内皮素(ET)、血管紧张素II(AngII)、心钠素(ANP)水平等的改变。结果鹿角方组的临床总有效率为82.5%,能显著提高EF和CO(P<0.05),降低IVST、PWT和LVMI(P<0.01),下调血浆ET、AngII和ANP水平(P<0.01),其疗效与卡托普利相当,并能显著改善肾虚症状,而地高辛或卡托普利组却未呈现该方面作用。结论鹿角方能加强心脏收缩功能、改善血流动力学,干预心室重构,从而延缓心力衰竭的进程。 To evaluate the intervention effect of "Lujlao Decoction" on left ventricular remodeling in patients with congestive heart failure (CHF). Methods 120 cases of CHF were randomly divided into Lujiao decoction group,digoxin group and captopril group. The total clinical effective rate,integra of the symptoms of renal asthenia,and ejection fraction(EF),cardiac output(CO),interventricular septal thicknass(IVST), posterior wall thickness(PWT) ,left ventricular mass index(LVMI) of echocowdio-gram as well as the measurement of plasma endothelin, angiotensin II and atrial natriuretic peptide were observed in three groups, Results The total clinical effective rate of Lujia.o decoction group was 82.5%, EF and CO were significantly improved(P 〈 0.05), IVST, PWT and LVMI were also reduced significantly (P 〈 0.01 ), the level of plasma ET, Ang Ⅱ and ANP was totally decreased significantly(P 〈 0.01 ),Its efficacy acted as well as that of captopril. The integra of the symptoms of renal asthenia was also decreased significantly (P 〈 0.01 ), however no significant difference in the captopril or digoxin group. Conclusion The Lujiao decoction is effective in enheneing cardiac contraction,improving hemodynamics preventing left ventricular from remodeling, so that it could postpone the processes of CHF.
出处 《上海中医药杂志》 北大核心 2006年第4期13-15,共3页 Shanghai Journal of Traditional Chinese Medicine
基金 国家中医药管理局资助项目(00-01LP45)
关键词 充血性心力衰竭 鹿角方 心室重构 内皮素 血管紧张素Ⅱ 心钠素 Congestive heart failure "Lujiao Decoction" ventricular remodeling endothelin angiotensin Ⅱ atrial natriuretic pcptidc
  • 相关文献

参考文献14

  • 1慢性收缩性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1):7-23. 被引量:2414
  • 2王宏宇,胡大一.心脏重构与心力衰竭(下)[J].中国医刊,2004,39(6):61-62. 被引量:5
  • 3Mckee PA,Castell WP,Mcnamara PM,et al.The natural history of congestive heart failure,the Framingham Study[J].N Engl J Med,1971,285:1441.
  • 4AHA Medical/scientific statement.1994 revisions to classification of functional capacity and objective assessment of patients with disease of the heart[J].Circulation,1994,90(1):644-645.
  • 5沈自尹.中医虚症辨证标准[J].中西医结合杂志,1986,5(10):698-698.
  • 6Devereux RB,Alonso DR,Lutas EM,et al.Echocardiographic assessmentof left ventricular hypertrophy:comparison to necropsy findings[J].Am J Cardiol,1986,57:450-455.
  • 7Davies MK.Digitalis:Still under suspicion (letter)[J].Lancet,1988,(2):401.
  • 8Schwartz SM,Duffy JY,Pearl JM,et al.Cellular and molecular aspects of myocardial dysfunction[J].Crit Care Med,2001,29 (10 Suppl):S214-219.
  • 9Schmieder RE.Mechanisms for the clinical benefits of angiotensin Ⅱ receptor blockers[J].Am J Hypertens,2005,18(5 Pt 1):720-730.
  • 10Kawai K,Hata K,Kawai H,et al.Pathophysiological characteristics and responsiveness to neurohormonal antagonism in idiopathic dilated cardiomyopathy patients with antihepatitis C virus antibody[J].Int Heart J,2005,46(3):407-417.

二级参考文献25

  • 1Madison DL, Pfeiffer SE. Cloning of the 3'end of rat bax-alpha and corresponding developmental down-regulation in differentiating primary, cultured oligodendrocytes [ J ]. Neurosci Lett, 1996,220 ( 3 ) :183-186.
  • 2Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure : National Hospital Discharge Survey 1985 to 1995[J]. Am Heart J,1999,137:352-60.
  • 3Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure : the Framingham Study [ J ] J Am Coil Cardiol 1993,22 ( 4Suppl A) :6A-13A.
  • 4Goncalves LM. Left ventricular dysfunction and cytoprotection [ J ].Rev Port Cardiol,2000,19Suppl 5 : V21-4.
  • 5Feuerstein G Z. Apoptosis - new opportunities for novel therapeutics for heart diseases [ J ]. Cardiovasc Drugs Ther, 2001,15 ( 6 ) : 547-51.
  • 6Ikdea S, Hamada M, Hiwada K. Contribution of non-cardiomyocyte apoptosis to cardiac remodelling that occurs in the transition from compensated hypertrophy to heart failure in spontaneously hypertensive rats[ J]. Clinical Science( Colch), 1999:97( 2 ) :239-46.
  • 7Fortuno MA, Ravassa S, Fortuno A, et al. Cardiomyocyte apoptotic cell death in arterial hypertension:mechanisms and potential management[ J]. Hypertension,2001,38(6) :1406-12.
  • 8Kang PM, Izumo S. Apoptosis and heart failure:A critical review of the literature[ J]. Circ Res ,2000,86( 11 ) : 1107-1113.
  • 9Mark DB, Shaw L, Harrell FE. Apoptosis in CHF induced by viral myocarditis in mice[ J]. Heart vessels. 1999,14( 1 ) :29-37.
  • 10Wilson S. Molecular and cellular mechanisms of myocardial failure[J]. Am-J- Cardiol, 1997,80(11A) :15L-25L.

共引文献2431

同被引文献235

引证文献17

二级引证文献105

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部